Capnocytophaga canimorsus peritonitis diagnosed by mass spectrometry in a diabetic patient undergoing peritoneal dialysis: a case report

Table 1 Summary of Capnocytophaga species peritonitis in PD patients

	Patient	PD duration	Species	Identification	Treatment	Outcome
Esteban et al. (1995) [5]	73 y, M	3 years	C. sputigena (putative)	Conventional biochemical assay with other laboratory tests	VCM + GM → ABPC + CPFX	Improved
Chadha et al. (1999) [17]	18 y, M	5 years	C. canimorsus	Unspecified	IP CEZ + TOB → IP TIPC + IV TOB + VCM → IP TIPC + CLDM	Catheter removal
Pers et al. (2007) [19]	67 y, M	2 years	C. cynodegmi	16S rRNA gene sequencing	IP GM + VCM → IV CXM + GM + MDZ	Catheter removal
Chow et al. (2010) [15]	39 y, F	3 years	Unknown	Unspecified	IP CEZ + CAZ	Improved
Sadjadi et al. (2012) [16]^a	83 y, M	2 years	Unknown	Conventional biochemical assay	IP VCM + CAZ (+ oral CPFX)	Catheter removal
Al-Fifi et al. (2013) [18]^a	49 y, M	1 year	C. canimorsus	16S rRNA gene sequencing	IP CEZ + TOB → IP CEZ + CPFX	Improved
Present case	49 y, F	1 year	C. canimorsus	MALDI-TOF mass spectrometry	IP CAZ	Improved

IP intraperitoneal, IV intravenous, VCM vancomycin, GM gentamycin, ABPC ampicillin, CPFX ciprofloxacin, CEZ cephazolin, TOB tobramycin, TIPC ticarcillin, CLDM clindamycin, CXM cefuroxime, MDZ metronidazole, CAZ ceftazidime, MALDI-TOF matrix-assisted laser desorption ionization-time of flight
^aThese cases were co-infected with Pasteurella multocida

ISSN: 1471-2369